TrialThe Prostate2026

Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809).

Anna C Ferrari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.